202
Participants
Start Date
May 10, 2020
Primary Completion Date
February 8, 2021
Study Completion Date
April 8, 2021
Ravulizumab
Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
BSC
Participants received medications, therapies, and interventions per standard hospital treatment protocols.
NYU Langone Health Center, New York
Icahn School of Medicine at Mount Sinai, New York
Westchester Medical Center, Valhalla
MedStar Georgetown University Hospital, Washington D.C.
Baltimore VA Medical Center, Baltimore
Hospital Universitario Ramon y Cajal, Madrid
Medical University of South Carolina, Charleston
University of Florida, Jacksonville
Mayo Clinic Florida, Jacksonville
Baptist Memorial Hospital, Memphis
Norton Healthcare, Louisville
Henry Ford Hospital, Detroit
Mayo Clinic Health System, La Crosse
Mayo Clinic Health System in Eau Claire, Eau Claire
Mayo Clinic, Rochester
Mayo Clinic Health System, Mankato
Rush University Medical Center, Chicago
Washington University School of Medicine, St Louis
Central Arkansas Veterans Healthcare System, Little Rock
Houston Methodist Hospital, Houston
LAC/USC Health Center, Los Angeles
Hôpital Raymond Poincaré, Garches
UC Irvine Medical Center, Orange
Hôpital Henri Mondor, Créteil
Hôpital Bicêtre, Le Kremlin-Bicêtre
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Boston Medical Center, Boston
Jikei University Hospital, Minato-Ku
Tokyo Medical University Hospital, Shinjuku-Ku
Medical Hospital, Tokyo Medical and Dental University, Bunkyō City
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clinic de Barcelona, Barcelona
King's College Hospital, London
Hammersmith Hospital, London
Royal Liverpool University Hospital, Liverpool
Queen Elizabeth Hospital, Birmingham
St James's University Hospital, Leeds
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY